JP2022537289A5 - - Google Patents

Info

Publication number
JP2022537289A5
JP2022537289A5 JP2021574798A JP2021574798A JP2022537289A5 JP 2022537289 A5 JP2022537289 A5 JP 2022537289A5 JP 2021574798 A JP2021574798 A JP 2021574798A JP 2021574798 A JP2021574798 A JP 2021574798A JP 2022537289 A5 JP2022537289 A5 JP 2022537289A5
Authority
JP
Japan
Prior art keywords
amino acid
antibody
acid sequence
antibody molecule
molecule
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021574798A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022537289A (ja
JP7716342B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/038143 external-priority patent/WO2020257289A2/en
Publication of JP2022537289A publication Critical patent/JP2022537289A/ja
Publication of JP2022537289A5 publication Critical patent/JP2022537289A5/ja
Application granted granted Critical
Publication of JP7716342B2 publication Critical patent/JP7716342B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021574798A 2019-06-17 2020-06-17 Cd138に対するヒト化抗体分子およびその使用 Active JP7716342B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962862457P 2019-06-17 2019-06-17
US62/862,457 2019-06-17
US202063035323P 2020-06-05 2020-06-05
US63/035,323 2020-06-05
PCT/US2020/038143 WO2020257289A2 (en) 2019-06-17 2020-06-17 Humanized antibody molecules to cd138 and uses thereof

Publications (3)

Publication Number Publication Date
JP2022537289A JP2022537289A (ja) 2022-08-25
JP2022537289A5 true JP2022537289A5 (cg-RX-API-DMAC7.html) 2023-06-26
JP7716342B2 JP7716342B2 (ja) 2025-07-31

Family

ID=71995040

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021574798A Active JP7716342B2 (ja) 2019-06-17 2020-06-17 Cd138に対するヒト化抗体分子およびその使用

Country Status (14)

Country Link
US (2) US12338291B2 (cg-RX-API-DMAC7.html)
EP (1) EP3983442A2 (cg-RX-API-DMAC7.html)
JP (1) JP7716342B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220044939A (cg-RX-API-DMAC7.html)
CN (1) CN114269786B (cg-RX-API-DMAC7.html)
AU (1) AU2020294696A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021025421A2 (cg-RX-API-DMAC7.html)
CA (1) CA3142021A1 (cg-RX-API-DMAC7.html)
IL (1) IL289034A (cg-RX-API-DMAC7.html)
MX (1) MX2021016098A (cg-RX-API-DMAC7.html)
MY (1) MY210065A (cg-RX-API-DMAC7.html)
PH (1) PH12021553109A1 (cg-RX-API-DMAC7.html)
TW (1) TW202112822A (cg-RX-API-DMAC7.html)
WO (1) WO2020257289A2 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL320863A (en) 2017-10-02 2025-07-01 Visterra Inc Antibodies to CD138 and their uses
BR112021025421A2 (pt) 2019-06-17 2022-02-01 Visterra Inc Moléculas de anticorpo humanizado para cd138 e os usos dos mesmos
WO2023275872A1 (en) * 2021-06-29 2023-01-05 Tel Hashomer Medical Research Infrastructure And Services Ltd. Diagnosis and treatment of pancreatic cancer
US20230348614A1 (en) * 2021-11-24 2023-11-02 Visterra, Inc. Engineered antibody molecules to cd138 and uses thereof
WO2023129995A2 (en) * 2021-12-30 2023-07-06 ST. JUDE CHILDREN'S RESEARCH HOSPITAL,Inc. Chimeric antigen receptors comprising a pdz binding motif
CN115960231B (zh) * 2022-09-28 2026-05-22 合肥天港免疫药物有限公司 抗cd138的抗体及其应用
WO2024102954A1 (en) 2022-11-10 2024-05-16 Massachusetts Institute Of Technology Activation induced clipping system (aics)
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
DE3689123T2 (de) 1985-11-01 1994-03-03 Xoma Corp Modulare einheit von antikörpergenen, daraus hergestellte antikörper und verwendung.
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・2・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
DE68927933T2 (de) 1988-09-02 1997-08-14 Dyax Corp Herstellung und auswahl von rekombinantproteinen mit verschiedenen bindestellen
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8905669D0 (en) 1989-03-13 1989-04-26 Celltech Ltd Modified antibodies
WO1991000906A1 (en) 1989-07-12 1991-01-24 Genetics Institute, Inc. Chimeric and transgenic animals capable of producing human antibodies
EP1690935A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
ES2139598T3 (es) 1990-07-10 2000-02-16 Medical Res Council Procedimientos para la produccion de miembros de parejas de union especifica.
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
ES2246502T3 (es) 1990-08-29 2006-02-16 Genpharm International, Inc. Animales no humanos transgenicos capaces de producir anticuerpos heterologos.
CA2090473A1 (en) 1990-08-29 1992-03-01 Robert M. Kay Homologous recombinatin in mammalian cells
DE69129154T2 (de) 1990-12-03 1998-08-20 Genentech, Inc., South San Francisco, Calif. Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
DE69233697T2 (de) 1991-03-01 2008-01-24 Dyax Corp., Cambridge Verfahren zur Entwicklung von bindenden Mikroproteinen
PT100379B (pt) 1991-04-10 1999-01-29 Scripps Research Inst Bibliotecas de receptores heterodimericos usando fagomideos
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
DE69334275D1 (de) 1992-08-21 2009-05-20 Univ Bruxelles Immunoglobuline ohne Leichtkette
EP1356093A2 (en) * 2000-06-21 2003-10-29 Hitachi Chemical Co., Ltd. Gene markers for lung cancer
AU2004224925C1 (en) 2004-08-30 2011-07-21 Biotest Ag Immunoconjugates targeting syndecan-1 expressing cells and use thereof
EP2551282A3 (en) 2005-03-23 2013-02-13 Genmab A/S Antibodies against CD38 for treatment of multiple myeloma
US20070054332A1 (en) 2005-08-10 2007-03-08 Alan Rapraeger Syndecan 1 ectodomain inhibits cancer
EP1914242A1 (en) 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
ES2475201T3 (es) 2007-12-26 2014-07-10 Biotest Ag Agentes dirigidos contra CD138 y usos de los mismos
PL2242772T3 (pl) 2007-12-26 2015-05-29 Biotest Ag Immunokonjugaty nakierowane na CD138 i ich zastosowanie
US9446146B2 (en) 2007-12-26 2016-09-20 Biotest Ag Methods and agents for improving targeting of CD138 expressing tumor cells
US9011864B2 (en) 2007-12-26 2015-04-21 Biotest Ag Method of decreasing cytotoxic side-effects and improving efficacy of immunoconjugates
CA2761120A1 (en) 2009-05-06 2010-11-11 Biotest Ag Uses of immunoconjugates targeting cd138
US9249467B2 (en) 2011-09-16 2016-02-02 Steven Goodison Bladder cancer detection composition, kit and associated methods
US10577543B2 (en) 2011-10-27 2020-03-03 Raymond Roger Wallage Efficient oil shale recovery method
US10117932B2 (en) 2011-12-08 2018-11-06 Biotest Ag Uses of immunoconjugates targeting CD138
CA2866612C (en) 2012-03-08 2018-01-16 Halozyme, Inc. Conditionally active ph-dependent cetuximab variant anti-epidermal growth factor receptor antibodies and method of use thereof
GB201216002D0 (en) 2012-09-07 2012-10-24 Deutsches Rheuma Forschungszentrum Berlin Drfz Compositions adn methods
US9803021B2 (en) 2012-12-07 2017-10-31 The Regents Of The University Of California CD138-targeted interferon demonstrates potent apoptotic and anti-tumor activities
CN103103197A (zh) 2013-01-30 2013-05-15 百奇生物科技(苏州)有限公司 抗cd138单克隆抗体可变区序列及其制备方法和应用
RU2611685C2 (ru) 2015-07-20 2017-02-28 Илья Владимирович Духовлинов Гуманизированное моноклональное антитело, специфичное к синдекану-1
CA3032820A1 (en) 2016-08-02 2018-03-22 Visterra, Inc. Engineered polypeptides and uses thereof
CN110691793A (zh) 2017-04-26 2020-01-14 田边三菱制药株式会社 黏结蛋白聚糖-1(cd138)结合剂及其用
IL320863A (en) 2017-10-02 2025-07-01 Visterra Inc Antibodies to CD138 and their uses
CN119405833A (zh) 2018-06-01 2025-02-11 卫材R&D管理有限公司 剪接调节抗体-药物缀合物及其使用方法
CA3141914A1 (en) 2019-06-07 2020-12-10 Adimab, Llc Engineered ph-dependent anti-cd3 antibodies, and methods for their generation and use
BR112021025421A2 (pt) 2019-06-17 2022-02-01 Visterra Inc Moléculas de anticorpo humanizado para cd138 e os usos dos mesmos
US12590171B2 (en) * 2019-09-27 2026-03-31 Nanjing GenScript Biotech Co., Ltd. Anti-VHH domain antibodies and use thereof
US20230348614A1 (en) 2021-11-24 2023-11-02 Visterra, Inc. Engineered antibody molecules to cd138 and uses thereof

Similar Documents

Publication Publication Date Title
JP7575102B2 (ja) Muc18に特異的な抗体
JP7526099B2 (ja) 抗cd38抗体の皮下投薬
CN110799539B (zh) 抗4-1bb抗体及其制备和使用方法
US20250236669A1 (en) Antibodies That Bind Human Cannabinoid 1 (CB1) Receptor
JP2024174865A (ja) ヘテロ二量体四価特異性抗体およびこれらの使用
JP7623939B2 (ja) 葉酸受容体アルファに特異的な抗体
ES2674175T3 (es) Anticuerpos anti-CD38 conjugados
JP7791836B2 (ja) 抗cd3抗体及びその使用
TWI717678B (zh) Pd-l1抗體、其抗原結合片段及醫藥用途
JP7656330B2 (ja) Cd44に特異的な抗体
DK2831113T3 (en) ANTIBODIES AGAINST BRADYKININ-B1 RECEPTOR LIGANDS
CA3054824A1 (en) Anti-icos agonist antibodies and uses thereof
CN114401744B (zh) 用于治疗癌症的抗cd33抗体
JP7578289B2 (ja) Muc18に特異的な抗体
JP2021501566A5 (cg-RX-API-DMAC7.html)
IL295494A (en) Anti-human cd19 antibodies
EP4110818A1 (en) C19 c38 bispecific antibodies
WO2023040940A1 (zh) Pvrig/tigit结合蛋白联合免疫检查点抑制剂用于治疗癌症
JP2023537078A (ja) COVID-19を治療及び防止するためのSARS-CoV-2抗体
CA3146933A1 (en) Radiolabeled met binding proteins for immuno-pet imaging
TWI879267B (zh) 抗人類pd-l1抗體及其用途
CN118871465A (zh) 针对btla的抗体及其用途
HK40128870A (zh) 抗人类pd-l1抗体及其用途
HK40114352A (en) Antibody against btla and uses thereof
TW202613175A (zh) Cdh3結合蛋白及其用途